• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market - Product Image

Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market

  • Published: September 2010
  • Region: Global
  • 101 Pages
  • GBI Research

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE

“Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The authors find that the global hepatitis therapeutics market is one of the growing markets of the pharmaceutical business. Due to the approval of potential new drugs as well as combinational therapies, the hepatitis market will grow further. Launch of drugs with significant READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Global Hepatitis Therapeutics Market: Introduction
2.1 Research Report Guidance

3 Global Hepatitis Therapeutics Market: Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Global Hepatitis Therapeutics Market
3.2.1 Sales Value
3.2.2 Treatment Usage Patterns
3.3 Hepatitis Market Drivers
3.3.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline
3.3.2 Promising Developments in Hepatitis C Pipeline
3.3.3 Steady Increase in Prescription Population
3.4 Hepatitis Market Restraints
3.4.1 Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase
3.4.2 Low Treatment Seeking Population
3.4.3 Loss of Exclusivity Protection in Hepatitis B Market
3.5 Generic Share in the Global Hepatitis Market

4 Global Hepatitis Market: Therapeutic Landscape
4.1 Introduction
4.1.1 Hepatitis A
4.1.2 Hepatitis B
4.2 Overview of Hepatitis A and B Vaccines Market
4.2.1 Sales Value
4.3 Hepatitis B Market
4.3.1 Introduction
4.3.2 Sales Value
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Usage Patterns
4.3.5 Geographical Segmentation
4.4 Hepatitis C Market
4.4.1 Introduction
4.4.2 Sales Value
4.4.3 Annual Cost of Therapy
4.4.4 Treatment Usage Patterns
4.4.5 Geographical Segmentation

5 Global Hepatitis Market: Geographical Landscape
5.1 Geographical Break-up
5.2 The US
5.2.1 Sales Value
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Top Five Countries in Europe
5.3.1 Sales Value
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns
5.4 Japan
5.4.1 Sales Value
5.4.2 Annual Cost of Therapy
5.4.3 Treatment Usage Patterns

6 Global Hepatitis Vaccines and Therapeutics Market: Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline – Hepatitis B Therapeutics
6.1.2 Research and Development Pipeline – Hepatitis C Therapeutics
6.2 Profiles of Key Late-Stage Vaccines in the Hepatitis A & B Market
6.2.1 Heplisav
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development
6.3.1 Entecavir + Adefovir combination therapy
6.3.2 Truvada (Tenofovir plus Emtricitabine combination therapy)
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development
6.4.1 Boceprevir (SCH 503034, narlaprevir)
6.4.2 Tenofovir + Emtricitabine Combination therapy
6.4.3 Zalbin (albinterferon alfa-2b, Joulferon)
6.4.4 Telaprevir (VX 905)
6.4.5 RG 7128

7 Global Hepatitis Vaccines & Therapeutics Market: Competitive Landscape
7.1 Market Share Analysis: Hepatitis
7.2 Competitive Profiling
7.2.1 Merck & Co., Inc
7.2.2 F. Hoffmann-La Roche Ltd
7.2.3 GlaxoSmithKline plc

8 Global Hepatitis Market: Strategic Consolidations
8.1 Mergers and Acquisitions
8.1.1 Overview
8.1.2 Summary of M&A Deals (2009-2010)
8.2 R&D Licensing Agreements
8.2.1 Summary of Licensing Deals (2009-2010)

9 Global Hepatitis Market: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.4.4 Forecasts
9.4.5 Expert Panel Validation
9.5 Contact Us
9.6 Disclaimer

1.1 List of Tables

Table 1: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001–2009
Table 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2009–2016
Table 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009
Table 4: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016
Table 5: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009
Table 6: Hepatitis Therapeutics Market, Global, Treatment Usage Patterns, 2009–2016
Table 7: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001–2009
Table 8: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2009–2016
Table 9: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001–2009
Table 10: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2009–2016
Table 11: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2001–2009
Table 12: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2009–2016
Table 13: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (‘000), 2001–2009
Table 14: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Usage Patterns (‘000), 2009–2016
Table 15: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001–2009
Table 16: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2009–2016
Table 17: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001–2009
Table 18: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2009–2016
Table 19: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2001–2009
Table 20: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2009–2016
Table 21: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2001–2009
Table 22: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2009–2016
Table 23: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2001–2009
Table 24: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation, 2009–2016
Table 25: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001–2009
Table 26: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2009–2016
Table 27: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001–2009
Table 28: Hepatitis Therapeutics Market, US, Sales Value ($m), 2009–2016
Table 29: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001–2009
Table 30: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2009–2016
Table 31: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (‘000), 2001–2009
Table 32: Hepatitis Therapeutics Market, US, Treatment Usage Patterns (‘000), 2009–2016
Table 33: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2001–2009
Table 34: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2009–2016
Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009
Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016
Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000), 2001–2009
Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (000’s), 2009–2016
Table 39: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001–2009
Table 40: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2009–2016
Table 41: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009
Table 42: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2016
Table 43: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2001–2009
Table 44: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2009–2016
Table 45: Final Prove 3 SVR Results for Telaprevir, HCV

1.2 List of Figures

Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2009
Figure 2: Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001–2016
Figure 3: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2016
Figure 4: Hepatitis Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016
Figure 5: Hepatitis Therapeutics Market, Global, Diseases Population, 2001–2016
Figure 6: Hepatitis Therapeutics Market, Global, Treatment Seeking Population, 2001–2016
Figure 7: Hepatitis Therapeutics Market, Global, Diagnosed Population, 2001–2016
Figure 8: Hepatitis Therapeutics Market, Global, Prescription Population, 2001–2016
Figure 9: Hepatitis B and Hepatitis C Therapeutic Market, Global, Branded and Generic Drugs (%), 2009
Figure 10: Hepatitis Therapeutics Market, Global, Hepatitis A and B Vaccines Sales Value ($m), 2001–2016
Figure 11: Hepatitis Therapeutics Market, Global, Hepatitis B-Genotypes Based on Geographic Origins
Figure 12: Hepatitis Therapeutics Market, Global, Hepatitis B Sales Value ($m), 2001–2016
Figure 13: Hepatitis Therapeutics Market, Global, Hepatitis B Annual Cost of Therapy ($), 2001–2016
Figure 14: Hepatitis Market, Global, Hepatitis B Treatment Usage Patterns, 2001–2016
Figure 15: Hepatitis Market, Global, Hepatitis B Diseased Population, 2001–2016
Figure 16: Hepatitis Therapeutics Market, Global, Hepatitis B Treatment Seeking Population, 2001–2016
Figure 17: Hepatitis Market, Global, Hepatitis B Diagnosis Population, 2001–2016
Figure 18: Hepatitis Therapeutics Market, Global, Hepatitis B Prescription Population, 2001–2016
Figure 19: Hepatitis Therapeutics Market, Global, Hepatitis B Market Segmentation by Geography (%), 2009 and 2016
Figure 20: Hepatitis Therapeutics Market, Global, Hepatitis B Market Geographical Segmentation ($m), 2001–2016
Figure 21: Hepatitis Therapeutics Market, Global, Hepatitis B Market, Geography Benchmarking, 2009
Figure 22: Hepatitis Therapeutics Market, Global, Hepatitis C Sales Value ($m), 2001–2016
Figure 23: Hepatitis Therapeutics Market, Global, Hepatitis C Annual Cost of Therapy ($), 2001–2016
Figure 24: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Usage Patterns, 2001–2016
Figure 25: Hepatitis Therapeutics Market, Global, Hepatitis C Diseased Population, 2001–2016
Figure 26: Hepatitis Therapeutics Market, Global, Hepatitis C Treatment Seeking Population, 2001–2016
Figure 27: Hepatitis Therapeutics Market, Global, Hepatitis C Diagnosis Population, 2001–2016
Figure 28: Hepatitis Therapeutics Market, Global, Hepatitis C Prescription Population, 2001–2016
Figure 29: Hepatitis Therapeutics Market, Global, Hepatitis C Market Segmentation by Geography (%), 2009 and 2016
Figure 30: Hepatitis Therapeutics Market, Global, Hepatitis C Geographical Market Segmentation ($m), 2001–2016
Figure 31: Hepatitis Therapeutics Market, Global, Hepatitis C Market, Geography Benchmarking, 2009
Figure 32: Hepatitis Therapeutics Market, Global, Market Share by Geography (%), 2009 and 2016
Figure 33: Hepatitis Therapeutics Market, Global, Sales Value by Geography ($m), 2001–2016
Figure 34: Hepatitis Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016
Figure 35: Hepatitis Therapeutics Market, US, Sales Value ($m), 2001–2016
Figure 36: Hepatitis Therapeutics Market, US, Annual Cost of Therapy ($), 2001–2016
Figure 37: Hepatitis Therapeutics Market, US, Treatment Usage Patterns, 2001–2016
Figure 38: Hepatitis Therapeutics Market, US, Diseased Population, 2001–2016
Figure 39: Hepatitis Therapeutics Market, US, Treatment Seeking Population, 2001–2016
Figure 40: Hepatitis Therapeutics Market, US, Diagnosed Population, 2001–2016
Figure 41: Hepatitis Therapeutics Market, US, Prescription Population, 2001–2016
Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Sales Value ($m), 2001–2016
Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016
Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Patterns, 2001–2016
Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001–2016
Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001–2016
Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population, 2001–2016
Figure 48: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001–2016
Figure 49: Hepatitis Therapeutics Market, Japan, Sales Value ($m), 2001–2016
Figure 50: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2016
Figure 51: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2001–2016
Figure 52: Hepatitis Therapeutics Market, Japan, Diseased Population, 2001–2016
Figure 53: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population, 2001–2016
Figure 54: Hepatitis Therapeutics Market, Japan, Diagnosed Population, 2001–2016
Figure 55: Hepatitis Therapeutics Market, Japan, Prescription Population, 2001–2016
Figure 56: Hepatitis Therapeutics Market, Global, R&D Pipeline by Indication (%), March 2010
Figure 57: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase (%), March 2010
Figure 58: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis B vaccines Market (%), March 2010
Figure 59: Hepatitis Therapeutics Market, Global, R&D Pipeline by Phase in Hepatitis C vaccines Market (%), March 2010
Figure 60: Hepatitis B and Hepatitis C Therapeutics Markets, Global, Market Share of Top Manufacturers (%), 2010
Figure 61: Hepatitis Vaccine Market, Global, Revenue of Top Players (%), 2010
Figure 62: Merck & Co., Inc., SWOT Analysis, 2010
Figure 63: F. Hoffmann-La Roche Ltd., SWOT Analysis, 2010
Figure 64: GlaxoSmithKline plc, SWOT Analysis, 2010
Figure 65: Hepatitis Therapeutics Market, Global, M&A Deals by Geography, (%), 2010
Figure 66: Hepatitis Therapeutics Health Market, Global, M&A Deals by Type, (%), 2010
Figure 67: Hepatitis Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2010
Figure 68: Research Market Forecasting Model

“Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market” provides in-depth analysis of the unmet needs, drivers and barriers that affect the global hepatitis therapeutic market. The report analyzes the markets for hepatitis in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Global Hepatitis Market is Forecast to Show High Growth

In 2009, the global hepatitis market was estimated to be worth $3,276m, representing a Compound Annual Growth Rate (CAGR) of 3.1% between 2001 and 2009. By 2016, the global hepatitis market is estimated to reach $5,977m, indicating a CAGR of 9% between 2009 and 2016.

The hepatitis A and hepatitis C markets are expected to grow at a high rate during the forecast period. The hepatitis B market alone is expects to witness a low growth.

The target patient base of the hepatitis market includes newly infected or diagnosed hepatitis patients, the treatment of non-responders and patients who discontinued treatment. Hence, there is a huge unmet need in the market. Also, the high cost of therapy has been a major concern for hepatitis patients.

Hepatitis Therapeutics Market, Global, Sales Value ($m), 2001–2016

Except for antivirals such as Ribavirin, all treatment therapeutics for hepatitis are biologics. The fact that cost of therapy for biologics is high; the annual cost of therapy for hepatitis is high as well.

The current hepatitis C pipeline does offer some promising novel products, and as a result the overall growth of the global hepatitis market is expected to show a moderate increase in the future.

- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos